{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=3",
    "query": {
      "intervention": "Placebo solution",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 3135,
    "total_pages": 314,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+solution&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T13:27:43.497Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03122223",
      "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP2438)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/AS01(B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2018-01-16",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122223"
    },
    {
      "nct_id": "NCT04317040",
      "title": "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Disease 2019 (COVID-19)"
      ],
      "interventions": [
        {
          "name": "Efprezimod alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2020-04-24",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 10,
      "location_summary": "Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317040"
    },
    {
      "nct_id": "NCT02239562",
      "title": "sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autoimmune Hepatitis"
      ],
      "interventions": [
        {
          "name": "sPIF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher O'Brien, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2014-11-14",
      "completion_date": "2016-12-29",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Cherry Hill, New Jersey",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239562"
    },
    {
      "nct_id": "NCT04511650",
      "title": "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "Razuprotafib Subcutaneous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Subcutaneous Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2020-10-21",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511650"
    },
    {
      "nct_id": "NCT02336308",
      "title": "A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thermal Hyperalgesia",
        "Anxiety",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-11-26",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02336308"
    },
    {
      "nct_id": "NCT03221569",
      "title": "Ketamine v. Ketorolac for Management of Generalized Tension Type Headache",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Intravenous ketamine",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Brooklyn Hospital Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2016-02-01",
      "completion_date": "2020-02-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221569"
    },
    {
      "nct_id": "NCT01844505",
      "title": "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 945,
      "start_date": "2013-06-11",
      "completion_date": "2024-04-19",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 46,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844505"
    },
    {
      "nct_id": "NCT03889639",
      "title": "Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "SAR442168",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 130,
      "start_date": "2019-03-29",
      "completion_date": "2020-01-02",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 9,
      "location_summary": "Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03889639"
    },
    {
      "nct_id": "NCT02257346",
      "title": "Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pregnancy"
      ],
      "interventions": [
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2014-11-01",
      "completion_date": "2015-02-15",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257346"
    },
    {
      "nct_id": "NCT03401073",
      "title": "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Idiopathic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-01",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-17T13:27:43.497Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401073"
    }
  ]
}